The trials showed an increase in interferon gamma (IFN-γ) and CSF eotaxins, which are associated with a slower cognitive decline in AD patients and a decrease in interleukin 6 (IL-6), which is associated with inflammatory states. Here, IL6 is linked to Alzheimer disease.